Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986489 |
| Synonyms | |
| Therapy Description |
Limited information is available on BMS-986489, a putative formulation of BMS-986012 and nivolumab (Feb 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986489 | BMS986489|BMS 986489 | Limited information is available on BMS-986489, a putative formulation of BMS-986012 and nivolumab (Feb 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06773910 | Phase II | Durvalumab BMS-986489 | BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (TIGOS-LS) | Recruiting | USA | 0 |